ATE494373T2 - Verfahren und zusammensetzungen zur verringerung von hcv virusgenommengen in einer zielzelle - Google Patents

Verfahren und zusammensetzungen zur verringerung von hcv virusgenommengen in einer zielzelle Download PDF

Info

Publication number
ATE494373T2
ATE494373T2 AT05749437T AT05749437T ATE494373T2 AT E494373 T2 ATE494373 T2 AT E494373T2 AT 05749437 T AT05749437 T AT 05749437T AT 05749437 T AT05749437 T AT 05749437T AT E494373 T2 ATE494373 T2 AT E494373T2
Authority
AT
Austria
Prior art keywords
target cell
methods
compositions
hcv virus
reducing amounts
Prior art date
Application number
AT05749437T
Other languages
English (en)
Inventor
Peter Sarnow
Catherine Jopling
Alissa Lancaster
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35320743&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE494373(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Application granted granted Critical
Publication of ATE494373T2 publication Critical patent/ATE494373T2/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/10—Production naturally occurring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AT05749437T 2004-05-04 2005-05-03 Verfahren und zusammensetzungen zur verringerung von hcv virusgenommengen in einer zielzelle ATE494373T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56835804P 2004-05-04 2004-05-04
PCT/US2005/015264 WO2005107816A2 (en) 2004-05-04 2005-05-03 Methods and compositions for reducing viral genome amounts in a target cell

Publications (1)

Publication Number Publication Date
ATE494373T2 true ATE494373T2 (de) 2011-01-15

Family

ID=35320743

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05749437T ATE494373T2 (de) 2004-05-04 2005-05-03 Verfahren und zusammensetzungen zur verringerung von hcv virusgenommengen in einer zielzelle

Country Status (15)

Country Link
US (6) US7307067B2 (de)
EP (3) EP1747023B2 (de)
JP (2) JP4943322B2 (de)
AT (1) ATE494373T2 (de)
AU (1) AU2005240118C1 (de)
CA (2) CA2912903A1 (de)
CY (1) CY1111755T1 (de)
DE (1) DE602005025751D1 (de)
DK (1) DK1747023T4 (de)
ES (1) ES2361458T5 (de)
IL (1) IL178679B (de)
PL (1) PL1747023T5 (de)
PT (1) PT1747023E (de)
SI (1) SI1747023T1 (de)
WO (1) WO2005107816A2 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1648914A4 (de) 2003-07-31 2009-12-16 Regulus Therapeutics Inc Oligomere verbindungen und zusammensetzungen zur verwendung bei der modulierung von kleinen nicht-kodienderen rnas
GB2424887B (en) * 2003-11-26 2008-05-21 Univ Massachusetts Sequence-specific inhibition of small RNA function
PL1747023T5 (pl) 2004-05-04 2017-05-31 Univ Leland Stanford Junior Sposób i kompozycje do zmniejszania ilości genomu wirusowego HCV w komórkach docelowych
EP2290071B1 (de) 2004-05-28 2014-12-31 Asuragen, Inc. Verfahren und Zusammensetzungen mit MicroRNA
WO2006137941A2 (en) * 2004-11-12 2006-12-28 Ambion, Inc. Methods and compositions involving mirna and mirna inhibitor molecules
US20060293267A1 (en) * 2005-04-13 2006-12-28 University Of Massachusetts Dual functional oligonucleotides for use as anti-viral agents
US20070213292A1 (en) 2005-08-10 2007-09-13 The Rockefeller University Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof
EP1919512B1 (de) * 2005-08-10 2014-11-12 Alnylam Pharmaceuticals Inc. Chemisch modifizierte oligonukleotide zur verwendung bei der modulierung von mikro-rna und ihre verwendungen
JP5523705B2 (ja) 2005-08-29 2014-06-18 レグルス・セラピューティクス・インコーポレイテッド Ｍｉｒ−１２２ａをモジュレートする使用方法
US7516342B2 (en) * 2005-12-30 2009-04-07 Intel Corporation Method, apparatus and system to dynamically choose an optimum power state
CA2649045C (en) 2006-04-03 2019-06-11 Santaris Pharma A/S Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
NZ571569A (en) * 2006-04-03 2011-09-30 Santaris Pharma As Pharmaceutical compositions comprising anti miRNA antisense oligonucleotides
EP2076599A2 (de) * 2006-09-19 2009-07-08 Asuragen, Inc. Mir-200-regulierte gene und wege als ziele für einen therapeutischen eingriff
WO2008113830A1 (en) 2007-03-22 2008-09-25 Santaris Pharma A/S Rna antagonist compounds for the inhibition of apo-b100 expression
DK2149605T3 (da) 2007-03-22 2013-09-30 Santaris Pharma As Korte RNA antagonist forbindelser til modulering af det ønskede mRNA
JP5149528B2 (ja) * 2007-03-30 2013-02-20 学校法人東京医科大学 Ｃ型肝炎ウイルスの複製を制御するマイクロｒｎａ
WO2009029681A2 (en) * 2007-08-27 2009-03-05 The Regents Of The University Of California Micrornas for inhibiting viral replication
US8361714B2 (en) 2007-09-14 2013-01-29 Asuragen, Inc. Micrornas differentially expressed in cervical cancer and uses thereof
WO2009043353A2 (en) * 2007-10-04 2009-04-09 Santaris Pharma A/S Micromirs
WO2009070805A2 (en) 2007-12-01 2009-06-04 Asuragen, Inc. Mir-124 regulated genes and pathways as targets for therapeutic intervention
US8404659B2 (en) * 2008-03-07 2013-03-26 Santaris Pharma A/S Pharmaceutical compositions for treatment of MicroRNA related diseases
EP2990487A1 (de) 2008-05-08 2016-03-02 Asuragen, INC. Zusammensetzungen und verfahren in zusammenhang mit der mirna-modulation von neovaskularisation oder angiogenese
EP2315832B1 (de) 2008-08-01 2015-04-08 Roche Innovation Center Copenhagen A/S Micro-rna-vermittelte modulation koloniestimulierender faktoren
US8691971B2 (en) 2008-09-23 2014-04-08 Scott G. Petersen Self delivering bio-labile phosphate protected pro-oligos for oligonucleotide based therapeutics and mediating RNA interference
EP2191834A1 (de) * 2008-11-26 2010-06-02 Centre National De La Recherche Scientifique (Cnrs) Zusammensetzungen und Verfahren zur Behandlung von Retrovireninfektionen
ES2599979T3 (es) * 2009-04-24 2017-02-06 Roche Innovation Center Copenhagen A/S Composiciones farmacéuticas para el tratamiento de pacientes de VHC que no responden al interferón
WO2011009697A1 (en) 2009-07-21 2011-01-27 Santaris Pharma A/S Antisense oligomers targeting pcsk9
DK2558578T3 (en) 2010-04-13 2016-01-25 Life Technologies Corp CONFIGURATIONS AND METHODS FOR INHIBITION OF nucleic acid function
LT2561078T (lt) 2010-04-23 2019-01-10 Cold Spring Harbor Laboratory Naujos struktūriškai sukonstruotos shrnr
US9045749B2 (en) 2011-01-14 2015-06-02 The General Hospital Corporation Methods targeting miR-128 for regulating cholesterol/lipid metabolism
WO2013040251A2 (en) 2011-09-13 2013-03-21 Asurgen, Inc. Methods and compositions involving mir-135b for distinguishing pancreatic cancer from benign pancreatic disease
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
SE1450131A1 (sv) 2011-10-21 2014-05-07 Abbvie Inc DAA-kombinationsbehandling (t.ex. med ABT-072 eller ABT-333)för användning vid behandling av HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
CN104383541A (zh) 2011-10-21 2015-03-04 艾伯维公司 用于治疗hcv的包含至少两种直接抗病毒剂和利巴韦林但无干扰素的方法
EP2992095B1 (de) 2013-05-01 2019-01-09 Regulus Therapeutics Inc. Microrna-verbindungen und verfahren zur modulation von mir-122
EP3591054A1 (de) 2013-06-27 2020-01-08 Roche Innovation Center Copenhagen A/S Gegen pcsk9 gerichtete antisense-oligomere und konjugate
EP3198012B1 (de) 2014-09-26 2019-09-04 University of Massachusetts Rna-modulierende stoffe
SG11201703646SA (en) 2014-11-10 2017-06-29 Glaxosmithkline Intellectual Property (No 2) Ltd Combination long acting compositions and methods for hepatitis c
CR20170191A (es) 2014-11-10 2017-09-29 Glaxosmithkline Intellectual Property (No 2) Ltd Composiciones farmacéuticas de acción prolongada para la hepatitis c
WO2017189978A1 (en) 2016-04-28 2017-11-02 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
TW202016302A (zh) 2018-05-08 2020-05-01 美商雷格勒斯治療公司 用於調節mir-122之微小rna化合物及方法
CN111904973B (zh) * 2020-07-27 2021-12-03 中国农业科学院兰州兽医研究所 ssc-miR-122在制备调节猪繁殖与呼吸综合征病毒复制的药物中的应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
ATE240401T1 (de) 1989-03-21 2003-05-15 Vical Inc Expression von exogenen polynukleotidsequenzen in wirbeltieren
US5610050A (en) * 1990-04-20 1997-03-11 The General Hospital Corporation Methods of preventing viral replication
JPH06311885A (ja) † 1992-08-25 1994-11-08 Mitsubishi Kasei Corp Ｃ型肝炎ウイルス遺伝子に相補的なアンチセンス化合物
US6423489B1 (en) † 1992-09-10 2002-07-23 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of Hepatitis C virus-associated diseases
US5985847A (en) 1993-08-26 1999-11-16 The Regents Of The University Of California Devices for administration of naked polynucleotides which encode biologically active peptides
JPH10503364A (ja) † 1994-05-10 1998-03-31 ザ ジェネラル ホスピタル コーポレーション Ｃ型肝炎ウイルスのアンチセンス阻害
US5922687A (en) 1995-05-04 1999-07-13 Board Of Trustees Of The Leland Stanford Junior University Intracellular delivery of nucleic acids using pressure
US5985310A (en) 1996-08-09 1999-11-16 Alcon Laboratories, Inc. Preservative systems for pharmaceutical compositions containing cyclodextrins
US6824768B2 (en) * 1998-12-18 2004-11-30 Schering Corporation Ribavirin-pegylated interferon alfa induction HCV combination therapy
JP2004532022A (ja) 2001-03-26 2004-10-21 サーナ・セラピューティクス・インコーポレイテッド Ｂ型肝炎ウイルスおよびｃ型肝炎ウイルスの複製のオリゴヌクレオチド媒介性阻害
WO2003029459A2 (en) * 2001-09-28 2003-04-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Micro-rna molecules
FR2830254B1 (fr) * 2001-09-28 2004-09-17 Synkem Nouvelles diphosphines, leurs complexes avec des metaux de transition et leur utilisation en synthese asymetrique
GB2397062B (en) 2002-02-20 2005-06-15 Sirna Therapeutics Inc RNA interference mediated inhibition of hepatitis c virus (HCV) gene expression using short interfering nucleic acid (siNA)
US20040175732A1 (en) * 2002-11-15 2004-09-09 Rana Tariq M. Identification of micrornas and their targets
CN1768139A (zh) * 2003-02-10 2006-05-03 独立行政法人产业技术总合研究所 通过dna干扰调控基因的表达
EP1596846A2 (de) * 2003-02-18 2005-11-23 Pfizer Inc. Zusammensetzungen enthaltend hepatitis c virus hemmer und deren verwendung zur behandlung
EP1648914A4 (de) 2003-07-31 2009-12-16 Regulus Therapeutics Inc Oligomere verbindungen und zusammensetzungen zur verwendung bei der modulierung von kleinen nicht-kodienderen rnas
US20070270361A1 (en) 2003-08-04 2007-11-22 Shan Lu Sars Nucleic Acids, Proteins, Vaccines, and Uses Thereof
CA2532795A1 (en) 2003-08-07 2005-02-17 Avi Biopharma, Inc. Sense antiviral compound and method for treating ssrna viral infection
GB2424887B (en) * 2003-11-26 2008-05-21 Univ Massachusetts Sequence-specific inhibition of small RNA function
PL1747023T5 (pl) 2004-05-04 2017-05-31 Univ Leland Stanford Junior Sposób i kompozycje do zmniejszania ilości genomu wirusowego HCV w komórkach docelowych
US20070213292A1 (en) 2005-08-10 2007-09-13 The Rockefeller University Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof
DK1931780T3 (en) 2005-08-29 2016-01-25 Regulus Therapeutics Inc Antisense-forbindelser med forøget anti-microrna-aktivitet
CA2649045C (en) 2006-04-03 2019-06-11 Santaris Pharma A/S Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
WO2009043353A2 (en) 2007-10-04 2009-04-09 Santaris Pharma A/S Micromirs
CA2804178C (en) 2009-06-29 2018-04-24 Rob Nielson A disc brake for a tape measure

Also Published As

Publication number Publication date
JP2012102116A (ja) 2012-05-31
EP2500431A3 (de) 2013-12-18
CY1111755T1 (el) 2015-10-07
US20150005362A1 (en) 2015-01-01
JP4943322B2 (ja) 2012-05-30
US8759312B2 (en) 2014-06-24
AU2005240118C1 (en) 2014-02-13
DE602005025751D1 (de) 2011-02-17
EP1747023A2 (de) 2007-01-31
ES2361458T3 (es) 2011-06-17
US7307067B2 (en) 2007-12-11
US20080234220A1 (en) 2008-09-25
PT1747023E (pt) 2011-04-11
AU2005240118A1 (en) 2005-11-17
US7838504B2 (en) 2010-11-23
SI1747023T1 (sl) 2011-06-30
DK1747023T4 (en) 2016-05-02
CA2912903A1 (en) 2005-11-17
EP2338996A2 (de) 2011-06-29
US8217020B2 (en) 2012-07-10
EP1747023B1 (de) 2011-01-05
EP2500431A2 (de) 2012-09-19
EP2338996A3 (de) 2013-12-18
PL1747023T3 (pl) 2011-08-31
JP5602123B2 (ja) 2014-10-08
US20110124707A1 (en) 2011-05-26
JP2007536242A (ja) 2007-12-13
PL1747023T5 (pl) 2017-05-31
EP1747023B2 (de) 2016-03-09
WO2005107816A2 (en) 2005-11-17
US9416362B2 (en) 2016-08-16
ES2361458T5 (es) 2016-04-20
WO2005107816A3 (en) 2006-02-23
CA2564503C (en) 2015-12-29
US20160348116A1 (en) 2016-12-01
AU2005240118B2 (en) 2011-09-08
CA2564503A1 (en) 2005-11-17
US20050288245A1 (en) 2005-12-29
EP1747023A4 (de) 2010-03-03
IL178679A0 (en) 2007-02-11
US20120329856A1 (en) 2012-12-27
DK1747023T3 (da) 2011-04-18
IL178679B (en) 2019-01-31

Similar Documents

Publication Publication Date Title
ATE494373T2 (de) Verfahren und zusammensetzungen zur verringerung von hcv virusgenommengen in einer zielzelle
WO2008033466A3 (en) Compositions and methods for treatment of viral diseases
EA200900298A1 (ru) Ингибиторы вируса гепатита с
EA200700243A1 (ru) Способы лечения гепатита с
WO2011123645A3 (en) Nucleoside phosphoramidates
WO2006012078A3 (en) Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection
WO2007084413A3 (en) Methods for treating hepatitis c
WO2005123087A3 (en) C-purine nucleoside analogs as inhibitors of rna-dependent rna viral polymerase
WO2007095269A3 (en) Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection
WO2008085508A3 (en) Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection
DE602006015861D1 (de) Antivirale verbindungen
EA200900297A1 (ru) Ингибиторы вируса гепатита с
WO2009091388A3 (en) Triazines and related compounds having antiviral activity, compositions and methods thereof
WO2008133753A3 (en) Anti-viral compounds
WO2007076034A3 (en) Anti-viral compounds
BRPI0811633A2 (pt) compostos de fórmulas (i) e (ii), método de tratamento de hospedeiro infectado por hiv-1, hiv-2, hbv ou hcv, método de prevenção de infecção por hiv-1, hiv-2, hbv ou hcv, método para reduzir atividade biológica de infecção por hiv-1, hiv-2, hbv ou hcv e composição farmacêutica
ATE522532T1 (de) Verbindungen zur behandlung von hepatitis c
WO2007084435A3 (en) Methods for treating hepatitis c
EP2399575A3 (de) Verfahren, Verwendungen und Zusammensetzungen zur Behandlung einer Infektion durch einen Virus aus der Familie der Flaviviridae durch Hemmung des Farnesoid X-Rezeptors (FXR)
ATE551343T1 (de) Tetracyclische verbindungen zur behandlung von hepatitis c
WO2010047830A3 (en) Agents for hcv treatment
WO2010055164A3 (en) Isoquinolone derivatives as inhibitors of plavivirus replication
ATE505473T1 (de) Cyclopropylkondensierte indolobenzazepinderivate zur behandlung von hepatitis c
WO2006085979A3 (en) Soluble forms of hendra and nipah virus g glycoprotein
ATE498398T1 (de) Cycloalkyl-heterozyklen zur behandlung des hepatitis-c-virus

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1747023

Country of ref document: EP